BCR-ABL1transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib-Reference-Cited by-同舟云学术

BCR-ABL1transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib

Published:2012-12-24 Issue:5 Volume:160 Page:630-639
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kim Dennis D.¹,Lee Honggi¹,Kamel-Reid Suzanne²,Lipton Jeffrey H.¹

Affiliation:

1. Department of Medical Oncology and Hematology; Princess Margaret Hospital; University Health Network; University of Toronto; Toronto; ON; Canada

2. Department of Pathology; Toronto General Hospital; University Health Network; University of Toronto; Toronto; ON; Canada

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12187/fullpdf

Reference14 articles.

1. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials;Branford;Blood,2008

2. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;New England Journal of Medicine,2006

3. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML);Hanfstein;Leukemia,2012

4. Dasatinib and Imatinib-induced reductions in BCR-ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of molecular response kinetics in the DASISION trial;Hochhaus;Blood,2011

5. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia;Hughes;New England Journal of Medicine,2003

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CFL1 is Implicated in Chronic Myeloid Leukemia Response during Imatinib Therapy;Journal of Cancer;2024

2. Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia;Pharmacology Research & Perspectives;2023-07-07

3. Exposure–Efficacy Analysis of Asciminib in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase;Clinical Pharmacology & Therapeutics;2022-07-31

4. Current status and novel strategy of CML;International Journal of Hematology;2021-03-29

5. Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2020-01